Abstract
Alzheimers disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDS). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDS cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.
Keywords: Alzheimer's disease, cyclooxygenases, non-steroidal anti-inflammatory drugs, docosahexaenoic acid, curcumin
CNS & Neurological Disorders - Drug Targets
Title: Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
Volume: 9 Issue: 2
Author(s): Greg M. Cole and Sally A. Frautschy
Affiliation:
Keywords: Alzheimer's disease, cyclooxygenases, non-steroidal anti-inflammatory drugs, docosahexaenoic acid, curcumin
Abstract: Alzheimers disease (AD) is accompanied by an activation of the innate immune system, and many epidemiological studies have shown reduced risk for dementia or AD associated with chronic consumption of non-steroidal anti-inflammatory drugs (NSAIDS). These observations led to animal model studies to test the hypothesis that NSAIDs can be disease-modifying for some aspects of AD pathogenesis. NSAIDS cannot only suppress inflammatory targets, which could contribute to neuroprotection, they also slow amyloid deposition by mechanisms that remain unclear. Several large clinical trials with NSAID therapies with AD subjects have failed, and cyclooxygenase-2 does not appear to be a useful target for disease modifying therapy. However, there may be apolipoprotein E E4 pharmacogenomic effects and a real but delayed positive signal in a large primary prevention trial with naproxen. This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review.
Export Options
About this article
Cite this article as:
Cole Greg M. and Frautschy Sally A., Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (2) . https://dx.doi.org/10.2174/187152710791011991
DOI https://dx.doi.org/10.2174/187152710791011991 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Aggregating Antibodies, a New Approach Towards Treatment of Conformational Diseases
Current Medicinal Chemistry Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews NAP Protects against Tau Hyperphosphorylation Through GSK3
Current Pharmaceutical Design Practical Lessons from Amyloid Immunotherapy Trials in Alzheimer Disease
Current Alzheimer Research Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Meet the Editorial Board
Current HIV Research Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design The Diagnostic Value of CSF Amyloid-β<sub>43</sub> in Differentiation of Dementia Syndromes
Current Alzheimer Research Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice
Current Alzheimer Research Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Aging - How Lifestyle Changes Could Prove to be an Effective Medicine for the Aging Cardiovascular System
Current Cardiology Reviews Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism